Since there are no established human autoimmune diseases containing autoantibodies against IL-2, MHC-DR or λ-LC, commercial antibodies, which produced robust signals in LIPS, were employed as positive controls (Fig 3B–3D). This evidence concerns the gene IL2 and autoimmune disease.